AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05944666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal technology (MT)
Description: Only fo the patients of the Main group. It will be different programms depending on severety of UL or LL paresis. Patients will receive a course of rehabilitation with multimodal correction using BFB-stabilometric training, cognitive-motor training with double and triple tasks once a day for the affected hand, virtual reality, functional individually programmed stimulation of antagonist muscles of the lower limb (FES), subject-manipulative activity training to restore fine movements of the hand on a glove simulator, in moderate paresis of the upper limb, the neurointerface Exokist-2 with EEG registration will be used. The program for IS patients includes 10 sessions in inpatient stage every day 15-30 min for the method, 15 sessions with the MT in outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
Study NCT05944666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation
Description: It will be different programms depending on severety of UL or LL paresis. Conventional rehabilitation (CR) includes physiotherapy, kinesiotherapy, occupational therapy. The program for IS patients consists of 10 sessions of every day trainings for inpatients stage, 15 sessions with the CR for outpatient stage: 15-30 minutes every method 2-3 times a week, 5-8 weeks.The total duration of one procedure is 2-3 hours.
Study NCT04842981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
Study NCT04842981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
Study NCT05797753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Tablet by oral administration
Study NCT05797753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Capsule by oral administration
Study NCT05262634 — intervention group
Intervention type: OTHER
Intervention: Data collection (laboratory and obstetric results)
Description: Maternal data: age, pregnancy, parity, singleton or multiple pregnancy, BMI, obstetric history data, and ethnicity.~Laboratory chemical results: hemoglobin (Hb), number of erythrocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), number of hypochromic erythrocytes (HRC), erythrocyte distribution width (EBW), ferritin, C reactive protein (CRP).~Maternal pregnancy outcomes and complications: Hb before and after delivery, mode of delivery, placenta abruption, preeclampsia/eclampsia, gestational diabetes, gestational cholestasis, pregnancy-induced hypertension, bacteriuria or urinary tract infections, peripartum and postpartum hemorrhage, puerperal infections, uterine subinvolution.~Perinatal outcomes: gestational age, birth weight, intrauterine growth retardation, preterm birth, macrosomia, premature rupture of membranes, Apgar score, intrauterine fetal death, pH values, admission to neonatology
Study NCT05005247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
Study NCT05797753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin ethyl succinate
Description: Tablet by oral administration
Study NCT05797753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Capsule by oral administration
Study NCT06470152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Correction strategy in reference to our PI-dependent clustering of sagittal alignment
Description: For type I patients (PI \< 39.56°), the target LL = -0.13\*PI2+9.36\*PI-134.08; for type II patients (39.56° ≤ PI \< 49.16°), the target LL = 0.45\*PI+26.57; for type III patients (49.16° ≤ PI \< 58.31°), the target LL = -0.15\*PI2+17.09\*PI-420.57; for type IV patients (PI > 58.31°), the target LL = 0.06\*PI2-7.55\*PI+289.77. Prediction intervals of 95% confidence is adopted as the target LL range.
Study NCT06470152 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Correction strategy in reference to the SAAS score
Description: This new score is composed of three sagittal parameters (PI-LL, PT and TPA). For these three parameters, points were assigned based on offset with age-adjusted targets 0 points if the parameter was within 10 years of the patient's age (Match). For each 20 years above the age-adjusted target, 1 point was added (e.g., + 1 point between + 10 and + 30, + 2 points between +30 and +50). Conversely, 1 point was subtracted for each 20 years below the age-adjusted target (e.g., -1 point between -10 and -30, -2 points between -30 and -50). SAAS was calculated by adding all 3 components, creating a discreet score that could have a negative value (under corrected) or positive value (over corrected). SAAS was sub-categorized into SAAS-Under if it was less than -1, SAAS-Match if it was between -1 and + 1 or SAAS-Over if it was greater than + 1.
Study NCT05512780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: An exploratory study of a single-arm, open design~All subjects enrolled will receive the following treatment:~Dalpiciclib combined with Letrozole, 28 days as one cycle.
Study NCT04858295 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Texting
Description: The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail, voice), self-administered surveys, and secure data capture for research purposes. Way to Health has been used successfully in prior behavior intervention studies.
Study NCT04858295 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth app
Description: Omron Connect app available on a participant's smartphone connects to the participant's home Omron blood pressure monitor via bluetooth technology. The Omron Connect app, which stores the blood pressure readings and provides reminders to the participant via push notifications also communicates with the Way to Health research platform via Internet connection.
Study NCT00311545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 328
Description: Anti-IL-6 chimeric monoclonal antibody
Study NCT04702594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy session via tools validated by MUSIC CARE
Description: Use of the MUSICARE tool, a digital space allowing access to different validated methods of music therapy. Music listening times are offered to patients with cognitive impairment with psycho-behavioral symptoms. The sessions are individual or group performed by a psychomotor therapist in UHR and volunteer caregivers trained in SRH. The sessions last on average 20-30min.
Study NCT06144723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20105
Description: Administered intravenously every 21 days.
Study NCT06585462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 513
Description: AMG 513 will be administered by SC or IV injection.
Study NCT06585462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by SC or IV injection.
Study NCT06424223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal Ridge augmentation
Description: A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel. A pouch is create between the bone and the matrix and the Biphasic Calcium Phosphate is inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures.
Study NCT05627557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered as per schedule specified in the respective arm.
Study NCT05627557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: MMF will be administered as per schedule specified in the respective arm.
Study NCT05627557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.
Study NCT05627557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.
Study NCT05627557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg (or 1.5 mg/kg if \</=45 kg) IV will be administered as premedication prior to infusions.
Study NCT05627557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/ Paracetamol
Description: Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.
Study NCT05627557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine Hydrochloride
Description: Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.
Study NCT06420297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Carbetocin nasal spray 3.2 mg three times daily (TID)
Study NCT06377540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive 200 mg Pembrolizumab on Day -28 and Day -6 by IV infusion.~Pembrolizumab 200 mg IV will resume at day 30+ after ASCT every 3 weeks for 1 year.
Study NCT06377540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
Study NCT06377540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Patient will receive a single dose of BCNU on day -6, dose of 300 mg/m2 by IV infusion.
Study NCT05974631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).
Study NCT05974631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Prolonged Exposure protocol
Description: DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).
Study NCT05974631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure therapy
Description: Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.
Study NCT05974631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Suicide risk management
Description: Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.
Study NCT06377540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be given at dose 100 mg/m2 BID intravenously on days -5, - 4, -3, and -2.
Study NCT06377540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine will be given at dose 100 mg/m2 BID intravenously on days -5, -4, - 3, and -2.
Study NCT06377540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be given at dose of 140 mg/m2 intravenously on day -1 in a single 20 minute infusion; dose will be based on actual body weight but capped at 3.6 mg/kg as part of BEAM conditioning.
Study NCT05333835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection
Description: HR17031 injection
Study NCT05333835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INS068 injection
Description: INS068 injection
Study NCT05333835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR20004 injection
Description: SHR20004 injection
Study NCT06298747 — intervention group
Intervention type: OTHER
Intervention: Selective cervical nerve root pulsed radiofrequency
Description: A 5-12 MHz linear US probe was used during the procedure. C7 has a more prominent posterior tubercle and a rudimentary anterior tubercle. C5 and C6 have more prominent and smooth anterior and posterior tubercles, respectively. After visualizing the hypoechoic nerve root between the tubercles of the transverse process, the surrounding vascular structures were identified and RF canula is used. After approaching the hypoechoic nerve root, after sensory and motor stimulation, PRF was applied to each nerve root.
Study NCT06139835 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tartarase
Description: Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus
Study NCT06139835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tartarase
Description: Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus
Study NCT05159245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: ALK
Study NCT05159245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: MEK1, MEK2
Study NCT05159245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Hedgehog
Study NCT05159245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Pertuzumab
Description: HER2
Study NCT05159245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: NTRK/ ROS1, ALK
Study NCT04853368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-576
Description: Oral capsules
Study NCT04853368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral capsules
Study NCT04853368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study NCT04853368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral capsules
Study NCT04853368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-119
Description: Oral capsules
Study NCT04785794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sing2016 M2SR H3N2 influenza vaccine
Description: This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later.
Study NCT05597189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Botanical extract
Study NCT05597189 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product consumption
Description: Product with identical characteristics to the experimental product.
Study NCT05159245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: PD-L1
Study NCT05159245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: BRAF V600
Study NCT05159245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: KIT/BRAF, RET
Study NCT05159245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: AR
Study NCT04785794 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive saline placebo administered intranasally on Day 1 followed by IIV at least 28 days later.
Study NCT05848128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Tavilermide ophthalmic solution
Description: Twice a day topicial dosing
Study NCT05848128 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ophthalmic solution
Description: Twice a day topical dosing
Study NCT04775264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Electric Field Ablation
Description: Catheter ablation of Ganglionated Plexi (GP) structures on the epicardial surface of the heart during cardiothoracic surgery
Study NCT06003088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653(5mg)
Description: Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
Study NCT06003088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653(25mg)
Description: Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
Study NCT05930184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peri-wound Transversus Abdominis Plane Block
Description: 0.25% bupivacaine 20ml was injected using no24 needle into a plane between internal oblique muscle and transversus abdominis muscle around every wound 2 cm. from wound opening. The procedure was confirmed by laparoscopic vision and the injection was done before removal of laparoscopic port.
Study NCT05930184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local wound infiltration
Description: 0.25% bupivacaine 20ml was injected using no24 needle into subcutaneous tissue after the abdominal sheet was sutured.
Study NCT04869306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel
Description: After lower third molar removal, the test group 1 will additionally receive hyaluronic acid gel prior to wound closure.
Study NCT04869306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel + carrier
Description: After lower third molar removal, the test group 2 will additionally receive hyaluronic acid gel with a collagen carrier prior to wound closure.
Study NCT05689229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: COVID-19 patients with secondary gram-negative bacterial infections receive colistin IV or aerosolized
Study NCT04900714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decremental PEEP
Description: High PEEP to low PEEP.
Study NCT04900714 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound score
Description: lung ultrasound to determine the extend of atelectasis. Uses validated lung ultrasound score.
Study NCT04900714 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood gas analysis
Description: Blood gas analysis to determine arterial oxygen tension
Study NCT04900714 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Registration of respiratory mechanics
Description: Pressures and volumes will be registered by the Fluxmed respiratory monitor (MBMED, Argentina)
Study NCT04294836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: BCM-95® (CURCUGREEN®) is a 100 percent pure extract of turmeric with enhanced bio-availability and bio-efficacy. Its powerful health-promoting benefits are derived from the colorful and aromatic qualities of the Indian spice
Study NCT04900714 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of dead space
Description: Dead space will be measured non-invasively using volumetric capnography on the FluxMed respiratory monitor (MBMED, Argentina)
Study NCT04294836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: PLACEBO Capsules 500mg
Study NCT04054050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light therapy
Description: Bright light (10,000 lux) therapy will be administered via a light box.
Study NCT04550234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad prolonged release HPMC capsule
Description: Randomized subjects will receive oral dose of verinurad HPMC capsule.
Study NCT04550234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol Tablet
Description: Randomized subjects will receive oral dose of allopurinol tablet.
Study NCT04550234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad/Allopurinol FDC Capsule
Description: Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule.